| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | David M Thomas | Q64605553 |
| Mrinal Gounder | Q92508279 | ||
| P2093 | author name string | William D Tap | |
| P2860 | cites work | Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone | Q24595521 |
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Activity of Sorafenib against desmoid tumor/deep fibromatosis | Q24620775 | ||
| Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor | Q27701677 | ||
| Patient-reported Symptoms of Tenosynovial Giant Cell Tumors | Q33793236 | ||
| A prognostic nomogram for prediction of recurrence in desmoid fibromatosis | Q33894889 | ||
| Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. | Q34023544 | ||
| Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. | Q34038265 | ||
| Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). | Q34077555 | ||
| A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells | Q34248681 | ||
| Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial | Q34575133 | ||
| Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology | Q34677531 | ||
| Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB | Q35084886 | ||
| Multinucleated cells in pigmented villonodular synovitis and giant cell tumor of tendon sheath express features of osteoclasts. | Q35764335 | ||
| Giant cell tumor of the pelvis and sacrum: 17 cases and analysis of the literature | Q35825707 | ||
| Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis | Q35994704 | ||
| Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study | Q36283018 | ||
| Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis | Q37876158 | ||
| RANKL, denosumab, and giant cell tumor of bone. | Q38009727 | ||
| Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). | Q38375349 | ||
| Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study | Q38448131 | ||
| Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis | Q38714796 | ||
| Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. | Q38836706 | ||
| Desmoid-Type Fibromatosis: Evolving Treatment Standards. | Q38945559 | ||
| Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. | Q39180339 | ||
| Giant-cell tumor of bone. A demographic, clinical, and histopathological study of all cases recorded in the Swedish Cancer Registry for the years 1958 through 1968 | Q39222074 | ||
| Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities | Q39346514 | ||
| Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. | Q41737244 | ||
| Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. | Q42648818 | ||
| Giant-cell tumor of bone | Q43856120 | ||
| Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). | Q46736556 | ||
| β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. | Q47106275 | ||
| Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). | Q47832940 | ||
| Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group | Q48714561 | ||
| Desmoid Tumors and Celecoxib with Sorafenib. | Q52939009 | ||
| CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. | Q53066623 | ||
| Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival. | Q53543228 | ||
| Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. | Q54436827 | ||
| Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. | Q54569245 | ||
| Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. | Q54731292 | ||
| Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone | Q57570810 | ||
| Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients | Q57571358 | ||
| Radiation therapy in the treatment of difficult giant cell tumors | Q69785274 | ||
| Expression of osteoclast differentiation signals by stromal elements of giant cell tumors | Q73711524 | ||
| A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014 | Q85329118 | ||
| Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma | Q86081506 | ||
| Notch inhibition in desmoids: "Sure it works in practice, but does it work in theory?" | Q86089261 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | connective tissue | Q25615 |
| P304 | page(s) | 202-209 | |
| P577 | publication date | 2017-12-08 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Locally Aggressive Connective Tissue Tumors | |
| P478 | volume | 36 |
| Q89823750 | Clinical Characteristics and Treatment of Intra-abdominal Aggressive Fibromatosis: A Retrospective Study of 16 Patients |
| Q90344251 | Molecular targets and novel therapeutic avenues in soft-tissue sarcoma |
| Q52639719 | Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. |
| Q91132351 | Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis |
| Q61893730 | Sorafenib for Advanced and Refractory Desmoid Tumors |
| Q64044245 | Tenosynovial Giant Cell Tumor of the Clinoid: Rare Condition |
Search more.